TechFlow news, October 15 — According to GLOBE NEWSWIRE, Propanc Biopharma, a biopharmaceutical company adopting an Ethereum treasury strategy, announced a strategic financing agreement with family office Hexstone Capital for up to $100 million.
Propanc CEO James Nathanielsz said the funding will accelerate the development of the company's clinical pipeline and plans to grow its digital asset treasury to $100 million or more within the next 12 months. Hexstone Capital has previously invested in multiple companies holding digital asset treasuries, involving various digital assets including BTC, ETH, SOL, and DOGE.
Earlier news: In early September, Propanc Biopharma announced plans to acquire $100 million worth of Ethereum.
Add to Favorites
Share to Social Media
